|

The Role of 18F-PSMA PET in Prostate Cancer Diagnosis in Equivocal MRI

RECRUITINGN/ASponsored by Chinese University of Hong Kong
Actively Recruiting
PhaseN/A
SponsorChinese University of Hong Kong
Started2026-10-07
Est. completion2027-12-31
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted

Summary

This study is a multi-center RCT to compare the clinically significant prostate cancer (csPCa) detection and/or change in clinical management in MRI guided (MRI arm) biopsy and MRI+18F-PSMA guided (Combined arm) biopsies in men with equivocal MRI prostate scans. If additional clinical value is shown by adding 18F-PSMA PET to equivocal MRI, then this should be the new standard of care.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Men ≥18 years of age
* Serum Prostate-specific antigen (PSA) 4-15 ng/mL, repeated at least once
* Prostate mpMRI done within 18 months
* MRI prostate with PI-RADS (11) scores of:

  * PI-RADS score 2 with red flag (PSA density \>0.2 OR Prostate health index, PHI\>35),
  * PI-RADS 3, OR
  * PI-RADS 4 with lower csPCa risks (PSAd \<0.1 OR PHI\<35)
* Normal Digital rectal examination
* Patient agrees for targeted and systematic prostate biopsy

Exclusion Criteria:

* Prostate biopsy within past 5 years
* Past or current history of prostate cancer
* Contraindicated to undergo PSMA PET-CT scan
* Contraindicated to prostate biopsy: active urinary tract infection, fail insertion of transrectal ultrasound probe into rectum (abdominal perineal resection, anal stenosis), fail to be placed in lithotomy position, uncorrectable coagulopathy, antiplatelet or anticoagulant which cannot be stopped (keep aspirin before and after biopsy is permitted)

Conditions2

CancerProstate Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.